A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy
Year: 2018
Type: article
Study design: Observational Study
Abstract: OBJECTIVE Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing. RESEARCH DESIGN AND METHODS We examined the relationship between T1D GRS, GADA (negative or positive), and rapid insulin requirement (within 5 years) using Kaplan-Meier survival analysis and Cox regression in 8,608 participants with clinical type 2 diabetes (onset >35 years and treated without insulin for ≥6 months). T1D GRS was both analyzed continuously (as standardized scores) and categorized based on previously reported centiles of a population with type 1 diabetes (<5th [low], 5th–50th [medium], and >50th [high]). RESULTS In GADA-positive participants (3.3%), those with higher T1D GRS progressed to insulin more quickly: probability of insulin requirement at 5 years (95% CI): 47.9% (35.0%, 62.78%) (high T1D GRS) vs. 27.6% (20.5%, 36.5%) (medium T1D GRS) vs. 17.6% (11.2%, 27.2%) (low T1D GRS); P = 0.001. In contrast, T1D GRS did not predict rapid insulin requirement in GADA-negative participants (P = 0.4). In Cox regression analysis with adjustment for age of diagnosis, BMI, and cohort, T1D GRS was independently associated with time to insulin only in the presence of GADA: hazard ratio per SD increase was 1.48 (1.15, 1.90); P = 0.002. CONCLUSIONS A T1D GRS alters the clinical implications of a positive GADA test in patients with clinical type 2 diabetes and is independent of and additive to clinical features.
Source: Diabetes Care
DOI: 10.2337/dc18-0431
Authors: Anita L. Grubb, Timothy J. McDonald, Femke Rutters, Louise A. Donnelly, Andrew T. Hattersley, Richard A. Oram, Colin N.A. Palmer, Amber A. van der Heijden, Fiona Carr, Petra J.M. Elders, Mike N. Weedon, Roderick C. Slieker, Leen M. ’t Hart, Ewan R. Pearson, Beverley M. Shields, Angus G. Jones
Institutions: University of Exeter, NIHR Exeter Clinical Research Facility, Royal Devon & Exeter NHS Foundation Trust, Royal Devon University Healthcare NHS Foundation Trust, Amsterdam Public Health, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Dundee, Ninewells Hospital, Leiden University Medical Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
Funders: University of Dundee, Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, National Institute for Health and Care Research, Diabetes UK, European Commission, ZonMw, Innovative Medicines Initiative, Medical Research Council, NIHR Exeter Clinical Research Facility
Awards: WTCCC2 core activities., MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND, DIabetes REsearCh on patient sTratification, WTCCC2 core activities, New insights from Neonatal Diabetes., Extreme Early onset Type 1 Diabetes, Urinary C-peptide creatinine ratio and glycaemic response to incretin based treatments in type 2 diabetes, G3207356259, G3529949959, G3725864416, G3738692396, G393177772, Preventing death and long term institutional care by developing a newborn screening strategy to Identify Neonatal Diabetes, G5702163051, Precision Medicine Exeter Innovation Platform (PMEI Platform): Proof of Concept Funds, NIHR Senior Investigator Award, WTCCC2 core activities., NIHR Senior Investigator Award, Stratified medicine in Type 2 diabetes: Insights from the study of drug response., Integrating clinical features and biomarkers to improve diabetes classification and treatment in young adults
OpenAlex ID: W2896006385
